HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare (Apr.13) - Trump's Tariffs on Pharmaceuticals, NSCEB's Report, RemeGen's Pain Point

Pre-IPO BenQ BM Holding (PHIP Updates) - Some Points Worth the Attention

China Healthcare Weekly (Apr.20)- Giant Biogene Announced a HK$2.3bn Placement, China's VBP Outlook

DeepSeek Ignites China Healthcare - The Investment Opportunities and Risks Behind

China Healthcare Weekly (Apr.6) - SASAC to Encourage SOE M&A, WuXi AppTec Disposed XDC Shares Again

DeekSeek May Not Be The "Game Changer" In China Healthcare - Time to Be Rational

China TCM (570.HK) - Updates on Performance Forecast and Valuation Outlook Based on 2024 Results

Thematic (Sector/Industry)

United states Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>APIs, generic drugs, CXO, low-end medical consumables will be hit the most due to tariffs.Investors are advised to be cautious on these subsectors as companies’ performance would be negatively affected. </li>
<li>As the tariff war is heating up, blood products, innovative medical device, innovative drugs, chain pharmacies, innovative medical services, pharmaceutical distribution business could be "safe haven assets" for investors. </li>
<li>The logic behind tariffs is to attack China's effective supply and trigger China's overcapacity problem, thereby weakening effective demand and reducing capital accumulation rate, so as to attack the RMB.</li>
</ul>


APIs, generic drugs, CXO, low-end medical consumables will be hit the most due to tariffs.Investors are advised to be cautious on these subsectors as companies’ performance would be negatively affected. 
As the tariff war is heating up, blood products, innovative medical device, innovative drugs, chain pharmacies, innovative medical services, pharmaceutical distribution business could be "safe haven assets" for investors. 
The logic behind tariffs is to attack China's effective supply and trigger China's overcapacity problem, thereby weakening effective demand and reducing capital accumulation rate, so as to attack the RMB.


Shanghai Pharmaceuticals Holding (601607 CH)

Beijing Tiantan Biological Products (600161 CH)

Hualan Biological Engineering (002007 CH)

Zhejiang Hisun Pharmaceutical Co, Ltd. (600267 CH)

Jiangxi Boya Bio Pharmaceutical (300294 CH)

Zhejiang Huahai Pharmaceutical Co, Ltd. (600521 CH)

Yixintang Pharmaceutical Group (002727 CH)

Shanghai RAAS Blood Products C (002252 CH)

DaShenLin Pharmaceutical Group (603233 CH)

Zylox-Tonbridge Medical Technology (2190 HK)

The Impact of Trump's Tariffs on China Healthcare - The Victims, And the Safe Haven Assets